Compare CRNC & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNC | MRVI |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.0M | 472.8M |
| IPO Year | 2019 | 2020 |
| Metric | CRNC | MRVI |
|---|---|---|
| Price | $7.18 | $3.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $11.50 | $4.00 |
| AVG Volume (30 Days) | 669.7K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.95 | 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $251,781,000.00 | $185,743,000.00 |
| Revenue This Year | $27.17 | $11.80 |
| Revenue Next Year | N/A | $7.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.94 | $1.67 |
| 52 Week High | $13.74 | $4.11 |
| Indicator | CRNC | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 35.44 | 39.04 |
| Support Level | $6.41 | $2.88 |
| Resistance Level | $11.87 | $3.99 |
| Average True Range (ATR) | 0.31 | 0.20 |
| MACD | 0.10 | -0.05 |
| Stochastic Oscillator | 31.53 | 10.53 |
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.